Physician's Orders

PEGFILGRASTIM/BIOSIMILAR
(NEULASTA/NEULASTA ONPRO/UDENYCA) - ADULT, OUTPATIENT, INFUSION CENTER

Page 1 to 2

Defaults for orders not otherwise specified below:

- Interval: Once
- Interval: Every ___ days

Duration:

- 1 Treatment
- Until date: __________
- 1 year
- _____# of Treatments

Anticipated Infusion Date __________. ICD 10 Code with Description ______________________

Height __________ (cm) Weight __________ (kg) Allergies ______________________

Provider Specialty

☐ Allergy/Immunology ☐ Infectious Disease ☐ OB/GYN ☐ Rheumatology
☐ Cardiology ☐ Internal Med/Family Practice ☐ Other ☐ Surgery
☐ Gastroenterology ☐ Nephrology ☐ Otolaryngology ☐ Urology
☐ Genetics ☐ Neurology ☐ Pulmonary ☐ Urology
☐ Cardiology ☐ Internal Med/Family Practice ☐ Other ☐ Surgery
☐ Gastroenterology ☐ Nephrology ☐ Otolaryngology ☐ Urology
☐ Genetics ☐ Neurology ☐ Pulmonary ☐ Urology

Site of Service

☐ SH Gerber ☐ SH Lemmen Holton (GR) ☐ SH Pennock ☐ SH United Memorial
☐ SH Helen DeVos (GR) ☐ SH Ludington ☐ SH Reed City ☐ SH Zeeland

Appointment Requests

☐ Infusion Appointment Request

Status: Future, Expected: S, Expires: S+365, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after, Injection and possible labs

Safety Parameters and Special Instructions

☐ ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 3

PEGFILGRASTIM (NEULASTA OR ONPRO ON BODY INJECTOR OR UDENYCA OR FULPHILIA):

Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

Pegfilgrastim and pegfilgrastim biosimilars are available in prefilled syringes for manual subcutaneous administration or as a kit for use with the On-body injector. Direct administration of doses less than 6 mg using the prefilled syringe is not recommended by the manufacturer (it does not have graduation marks necessary for accurate measurement of doses other than 6 mg); use caution to avoid dosing errors.

Pegfilgrastim-jmdb (Fulphila) and pegfilgrastim-cbqv (Udenyca) are approved as biosimilars to pegfilgrastim (Neulasta).

On-body injector: A health care provider must fill the On-body injector prior to applying to the patient’s skin. The On-body delivery system may be applied on the same day as chemotherapy administration as long as pegfilgrastim is delivered no less than 24 hours after chemotherapy is administered. The On-body injector system will deliver pegfilgrastim over about 45 minutes approximately 27 hours after application. Do not expose the On-body injector to oxygen-rich environments (eg, hyperbaric chambers), MRI, x-ray (including airport x-ray), CT-scan, ultrasound, or radiation treatment (may damage injector system). Keep the On-body injector at least 4 inches away from electrical equipment, including cell phones, cordless phones, microwaves, and other common appliances (injector may not work properly).

Labs

☐ Complete Blood Count w/Differential


☐ Lab: ____________________________ ☐ Every ___ days ☐ Until date: __________
☐ Once ☐ 1 year ☐ _____# of Treatments

CONTINUED ON PAGE 2 ➔

NOTE: Epic Treatment/Therapy Plan Orders. To be scanned/attached to the appropriate Infusion Referral Order in Epic.
Medications

<table>
<thead>
<tr>
<th>☑ Pegfilgrastim Neulasta Onpro Or Neulasta Prefilled Syringe OR Udenyca Prefilled Syringe</th>
</tr>
</thead>
<tbody>
<tr>
<td>○ pegfilgrastim (NEULASTA ONPRO) injection 6 mg</td>
</tr>
<tr>
<td>6 mg, OnBody Injector, Once, Starting S, For 1 Doses</td>
</tr>
<tr>
<td>Apply filled device onto patient’s intact skin on back of arm or abdomen. Refrigerate.</td>
</tr>
</tbody>
</table>

| ○ pegfilgrastim (NEULASTA) prefilled syringe 6 mg |
| 6 mg, Subcutaneous, Once, Starting S, For 1 Doses |
| pegfilgrastim (Neulasta) SHOULD NOT be given for at least 24 hours FOLLOWING chemotherapy. Refrigerate. |

| ○ pegfilgrastim-cbqv (UDENYCA) prefilled syringe 6 mg (PREFERRED FORMULARY) |
| 6 mg, Subcutaneous, Once, Starting S, For 1 Doses |
| pegfilgrastim-cbqv (UDENYCA) SHOULD NOT be given for at least 24 hours FOLLOWING chemotherapy. Refrigerate. |
| **Udenyca is the preferred SH biosimilar product.** |

| ○ pegfilgrastim-jmdb (FULPHILA) prefilled syringe 6 mg |
| 6 mg, Subcutaneous, Once, Starting S, For 1 Doses |
| pegfilgrastim-jmdb (FULPHILA) SHOULD NOT be given for at least 24 hours FOLLOWING chemotherapy. Refrigerate. |